Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
Background: Osteoporotic hip fractures are on the raise in the world. Denosumab and zoledronic acid are among the commonly used current anti-osteoporotic medications to reduce hip fractures. The purpose of the present study was to compare the effectiveness and adverse events of denosumab and zoled...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Journal of Surgical Specialties and Rural Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/jssr/fulltext/2024/05010/role_of_denosumab_and_zoledronic_acid_in_geriatric.5.aspx |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850100243792658432 |
|---|---|
| author | P Madhuchandra S Nandeesh K P Raju |
| author_facet | P Madhuchandra S Nandeesh K P Raju |
| author_sort | P Madhuchandra |
| collection | DOAJ |
| description | Background:
Osteoporotic hip fractures are on the raise in the world. Denosumab and zoledronic acid are among the commonly used current anti-osteoporotic medications to reduce hip fractures. The purpose of the present study was to compare the effectiveness and adverse events of denosumab and zoledronic acid in geriatric patients after a hip fracture.
Materials and Methods:
A prospective observational study was conducted between February 2020 and May 2021, and a total of 104 patients were included in the study. Fifty-three patients were given subcutaneous (SC) denosumab once in 6 months, and 51 patients were given intravenous (IV) zoledronic acid. The percentage changes in the Bone Mineral Density (BMD) values from the baseline values were compared between both the groups at 0, 12, and 24 months.
Results:
The percentage increase in lumbar-bone mineral density (L-BMD) was higher significantly in the denosumab group when compared to the zoledronic acid group at 12 months (6.8 ± 0.9 vs. 4.5 ± 0.7; P < 0.01) and 24 months (9.2 ± 0.9 vs. 7.1 ± 0.8; P < 0.001). There was a significant percentage change in the hip-bone mineral density (BMD) in both the groups; however, a higher mean percentage change was noted in the denosumab group when compared to the zoledronic acid group at 12 months and 24 months (P < 0.04 and P < 0.001).
Conclusion:
We conclude that SC-given denosumab has got a better efficacy on comparison with the IV-given zoledronic acid. Randomized control trials with a large sample size and longer follow-up are required to come to conclusion regarding patient safety, compliance, and persistence. |
| format | Article |
| id | doaj-art-f2c890450df74daa8a65f7abeb784d5a |
| institution | DOAJ |
| issn | 2772-3151 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Surgical Specialties and Rural Practice |
| spelling | doaj-art-f2c890450df74daa8a65f7abeb784d5a2025-08-20T02:40:20ZengWolters Kluwer Medknow PublicationsJournal of Surgical Specialties and Rural Practice2772-31512024-01-0151202310.4103/jssrp.jssrp_4_24Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative AnalysisP MadhuchandraS NandeeshK P RajuBackground: Osteoporotic hip fractures are on the raise in the world. Denosumab and zoledronic acid are among the commonly used current anti-osteoporotic medications to reduce hip fractures. The purpose of the present study was to compare the effectiveness and adverse events of denosumab and zoledronic acid in geriatric patients after a hip fracture. Materials and Methods: A prospective observational study was conducted between February 2020 and May 2021, and a total of 104 patients were included in the study. Fifty-three patients were given subcutaneous (SC) denosumab once in 6 months, and 51 patients were given intravenous (IV) zoledronic acid. The percentage changes in the Bone Mineral Density (BMD) values from the baseline values were compared between both the groups at 0, 12, and 24 months. Results: The percentage increase in lumbar-bone mineral density (L-BMD) was higher significantly in the denosumab group when compared to the zoledronic acid group at 12 months (6.8 ± 0.9 vs. 4.5 ± 0.7; P < 0.01) and 24 months (9.2 ± 0.9 vs. 7.1 ± 0.8; P < 0.001). There was a significant percentage change in the hip-bone mineral density (BMD) in both the groups; however, a higher mean percentage change was noted in the denosumab group when compared to the zoledronic acid group at 12 months and 24 months (P < 0.04 and P < 0.001). Conclusion: We conclude that SC-given denosumab has got a better efficacy on comparison with the IV-given zoledronic acid. Randomized control trials with a large sample size and longer follow-up are required to come to conclusion regarding patient safety, compliance, and persistence.https://journals.lww.com/jssr/fulltext/2024/05010/role_of_denosumab_and_zoledronic_acid_in_geriatric.5.aspxdenosumab; osteoporosis; zoledronic acid |
| spellingShingle | P Madhuchandra S Nandeesh K P Raju Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis Journal of Surgical Specialties and Rural Practice denosumab; osteoporosis; zoledronic acid |
| title | Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis |
| title_full | Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis |
| title_fullStr | Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis |
| title_full_unstemmed | Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis |
| title_short | Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis |
| title_sort | role of denosumab and zoledronic acid in geriatric hip fractures a comparative analysis |
| topic | denosumab; osteoporosis; zoledronic acid |
| url | https://journals.lww.com/jssr/fulltext/2024/05010/role_of_denosumab_and_zoledronic_acid_in_geriatric.5.aspx |
| work_keys_str_mv | AT pmadhuchandra roleofdenosumabandzoledronicacidingeriatrichipfracturesacomparativeanalysis AT snandeesh roleofdenosumabandzoledronicacidingeriatrichipfracturesacomparativeanalysis AT kpraju roleofdenosumabandzoledronicacidingeriatrichipfracturesacomparativeanalysis |